We are live on
!
Find out more
Rafferty Asset Management Portfolio holdings
AUM
$24.6B
1-Year Est. Return
47.06%
This Fund
S&P 500
This Quarter
Est. Return
+8.79%
1 Year Est. Return
+47.06%
3 Year Est. Return
+108.18%
5 Year Est. Return
+135.84%
10 Year Est. Return
+427.13%
AUM
$17.7B
AUM Growth
+$2.98B
(+20%)
Cap. Flow
+$1.81B
Cap. Flow
% of AUM
10.19%
Top 10 Holdings %
Top 10 Hldgs %
35.18%
Holding
1,173
New
33
Increased
727
Reduced
328
Closed
84
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$505M |
| 2 |
Intel
INTC
|
+$122M |
| 3 |
Apple
AAPL
|
+$122M |
| 4 |
Microsoft
MSFT
|
+$98.1M |
| 5 |
Invesco QQQ Trust
QQQ
|
+$97.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$90.1M |
| 2 |
VanEck Gold Miners ETF
GDX
|
+$37.3M |
| 3 |
iShares MSCI Brazil ETF
EWZ
|
+$32.8M |
| 4 |
State Street SPDR Bloomberg High Yield Bond ETF
JNK
|
+$15.9M |
| 5 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
+$15.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 45.79% |
| 2 | Financials | 10.21% |
| 3 | Healthcare | 7.68% |
| 4 | Consumer Discretionary | 4.29% |
| 5 | Energy | 4.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
276
United Therapeutics
UTHR
$26.2B
| $8.02M | 0.05% |
36,314
+6,523
| +22% | +$1.44M |
|
277
HP
HPQ
$24.6B
| $8.02M | 0.05% |
261,019
+59,029
| +29% | +$1.77M |
|
|
SWN
278
DELISTED
Southwestern Energy Company
SWN
| $8M | 0.05% |
1,331,750
-432,350
| -25% | -$2.23M |
|
|
KDNY
279
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $8M | 0.05% |
208,207
+27,133
| +15% | +$697K |
|
280
Gartner
IT
$10.2B
| $7.99M | 0.05% |
22,819
+5,725
| +33% | +$1.86M |
|
281
Roivant Sciences
ROIV
$24.8B
| $7.99M | 0.05% |
792,631
-56,075
| -7% | -$502K |
|
282
East-West Bancorp
EWBC
$17.9B
| $7.93M | 0.04% |
150,274
+34,553
| +30% | +$1.75M |
|
283
CrowdStrike
CRWD
$189B
| $7.91M | 0.04% |
215,544
+25,156
| +13% | +$876K |
|
|
KRTX
284
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $7.91M | 0.04% |
36,477
-1,478
| -4% | -$317K |
|
|
MRTX
285
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $7.9M | 0.04% |
218,639
+45,123
| +26% | +$1.86M |
|
286
Deere & Co
DE
$162B
| $7.9M | 0.04% |
19,492
+1,838
| +10% | +$703K |
|
287
Protagonist Therapeutics
PTGX
$8.92B
| $7.88M | 0.04% |
285,459
+132,072
| +86% | +$3.31M |
|
288
BioMarin Pharmaceuticals
BMRN
$11.7B
| $7.88M | 0.04% |
90,874
+15,624
| +21% | +$1.47M |
|
289
Relay Therapeutics
RLAY
$4.24B
| $7.88M | 0.04% |
627,013
+183,387
| +41% | +$2.28M |
|
290
PTC Therapeutics
PTCT
$6.26B
| $7.85M | 0.04% |
193,115
+35,672
| +23% | +$1.75M |
|
291
Insmed
INSM
$22B
| $7.83M | 0.04% |
371,126
-7,122
| -2% | -$135K |
|
292
Cullen/Frost Bankers
CFR
$10.3B
| $7.78M | 0.04% |
72,380
+17,908
| +33% | +$1.87M |
|
293
Equinix
EQIX
$103B
| $7.78M | 0.04% |
9,922
+201
| +2% | +$147K |
|
|
SNV
294
DELISTED
Synovus
SNV
| $7.75M | 0.04% |
256,307
+84,166
| +49% | +$2.46M |
|
295
Zscaler
ZS
$24B
| $7.75M | 0.04% |
52,991
-3,520
| -6% | -$430K |
|
296
Corning
GLW
$116B
| $7.75M | 0.04% |
221,170
+56,555
| +34% | +$1.86M |
|
297
Webster Financial
WBS
$12.5B
| $7.73M | 0.04% |
204,647
+62,681
| +44% | +$2.31M |
|
298
Ironwood Pharmaceuticals
IRWD
$614M
| $7.72M | 0.04% |
725,171
+102,996
| +17% | +$1.11M |
|
299
Travere Therapeutics
TVTX
$5.33B
| $7.65M | 0.04% |
498,252
+171,782
| +53% | +$3.12M |
|
300
Vir Biotechnology
VIR
$1.5B
| $7.65M | 0.04% |
311,840
+10,994
| +4% | +$276K |
|
Similar funds
CS
AF
SC
JG
Rafferty Asset Management's Q2 2023 Portfolio in Review
As of Q2 2023, Rafferty Asset Management held 1,173 positions worth $17.7B, up 20% from $14.8B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Rafferty Asset Management deployed $1.81B of net new capital in Q2 2023, opening 33 new positions and adding to 727 existing holdings. Its largest new stake was Biomea Fusion: 136,903 shares worth $3.01M.
By sector, the portfolio is most concentrated in Technology at 46% of assets, up from 42% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was NVIDIA, an estimated $90.1M trimmed.
- Rafferty Asset Management's largest Q2 2023 buy was Biomea Fusion: 136,903 shares worth $3.01M.
- Rafferty Asset Management added most to iShares 20+ Year Treasury Bond ETF in Q2 2023, an estimated $505M increase.
- Rafferty Asset Management's biggest Q2 2023 reduction was NVIDIA, cutting an estimated $90.1M.
- Rafferty Asset Management fully exited Prometheus Biosciences, Inc. Common Stock in Q2 2023, selling an estimated $6.38M.
- Rafferty Asset Management's ten largest holdings make up 35% of its $17.7B portfolio in Q2 2023.
- Rafferty Asset Management opened 33 new positions and closed 84 in Q2 2023.
- Rafferty Asset Management's portfolio value rose 20% quarter-over-quarter to $17.7B.
Based on Rafferty Asset Management's 13F filing for Q2 2023, filed 11 Aug 2023.